NZ760537A - Dual mode radiotracer and -therapeutics - Google Patents

Dual mode radiotracer and -therapeutics

Info

Publication number
NZ760537A
NZ760537A NZ760537A NZ76053718A NZ760537A NZ 760537 A NZ760537 A NZ 760537A NZ 760537 A NZ760537 A NZ 760537A NZ 76053718 A NZ76053718 A NZ 76053718A NZ 760537 A NZ760537 A NZ 760537A
Authority
NZ
New Zealand
Prior art keywords
radiotracer
therapeutics
dual mode
sifa
silicon
Prior art date
Application number
NZ760537A
Other languages
English (en)
Inventor
Alexander Josef Wurzer
Hans-Jürgen Wester
Matthias Johannes Eiber
Original Assignee
Univ Muenchen Tech
Technische Univ Munchen Klinikum Rechts Der Isar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech, Technische Univ Munchen Klinikum Rechts Der Isar filed Critical Univ Muenchen Tech
Publication of NZ760537A publication Critical patent/NZ760537A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nuclear Medicine (AREA)
NZ760537A 2017-07-28 2018-07-30 Dual mode radiotracer and -therapeutics NZ760537A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Publications (1)

Publication Number Publication Date
NZ760537A true NZ760537A (en) 2026-01-30

Family

ID=59501286

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ760537A NZ760537A (en) 2017-07-28 2018-07-30 Dual mode radiotracer and -therapeutics

Country Status (21)

Country Link
US (4) US11413360B2 (https=)
EP (3) EP4424378A3 (https=)
JP (2) JP7059372B2 (https=)
KR (2) KR102752620B1 (https=)
CN (1) CN111132700B (https=)
AU (2) AU2018308699B2 (https=)
BR (1) BR112020001785A2 (https=)
CA (1) CA3071315A1 (https=)
DK (1) DK3658194T3 (https=)
EA (1) EA202090370A1 (https=)
ES (1) ES3011272T3 (https=)
FI (1) FI3658194T3 (https=)
HU (1) HUE070098T2 (https=)
IL (2) IL318092A (https=)
MX (2) MX2020000352A (https=)
NZ (1) NZ760537A (https=)
PL (1) PL3658194T3 (https=)
PT (1) PT3658194T (https=)
SG (1) SG11202000725WA (https=)
WO (1) WO2019020831A1 (https=)
ZA (1) ZA202000467B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE070098T2 (hu) * 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
BR112021012110A2 (pt) 2019-01-30 2021-09-08 Technische Universität München Radiofarmacêuticos substituídos por aceptor de fluoreto de silício
CA3128406A1 (en) * 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
WO2022018264A1 (en) 2020-07-23 2022-01-27 Technische Universität München Silicon-containing ligand compounds
AU2021336987A1 (en) 2020-09-03 2023-04-06 Curium Us Llc Radiolabeling and formulation for scale up of 64Cu-dotatate
EP4023250A1 (en) 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
AU2022219543A1 (en) * 2021-02-15 2023-08-17 Technische Universität München Dual mode radiotracer and therapeutics
IL307381A (en) * 2021-04-02 2023-11-01 Advanced Accelerator Applications Diagnostic methods of prostate cancer
MX2023013485A (es) * 2021-05-14 2023-12-07 Univ Muenchen Tech Radiofarmacos ligandos del receptor de la somatostatina y precursores de los mismos.
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP4380629A1 (en) * 2021-08-05 2024-06-12 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
JP2025525111A (ja) 2022-07-29 2025-08-01 テクニシェ ユニバーシタット ミュンヘン 放射性医薬品のためのケイ素系フッ化物アクセプター基
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
AU2023345654A1 (en) * 2022-09-20 2025-02-27 Technische Universität München Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy
KR20250073273A (ko) 2022-09-23 2025-05-27 누클리디움 아게 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
AU2023379454A1 (en) * 2022-11-14 2025-05-29 Aktis Oncology, Inc. Decreased retention of miniproteins in kidney
TW202530249A (zh) 2023-09-29 2025-08-01 美商雅克提斯腫瘤學公司 小蛋白、結合物及其用途
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
WO2025250644A1 (en) * 2024-05-28 2025-12-04 Case Western Reserve University Fluorescent nuclide-containing agents for detecting and treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
JP2005519861A (ja) * 2001-07-27 2005-07-07 ターゲサム・インコーポレーテッド 治療剤及び撮像剤としての脂質構築物
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
RU2743781C2 (ru) * 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP3209336B1 (en) 2014-10-20 2019-12-11 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
US10800797B2 (en) * 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
HUE070098T2 (hu) 2017-07-28 2025-05-28 Univ Muenchen Tech Kettõs módusú radioaktív jelzõ és terapeutikumok
BR112020011727A2 (pt) * 2017-12-11 2020-11-17 Technische Universität München ligantes de psma para imageamento e endorradioterapia
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство

Also Published As

Publication number Publication date
US11413360B2 (en) 2022-08-16
US20260021211A1 (en) 2026-01-22
EP3658194A1 (en) 2020-06-03
MX2023007914A (es) 2023-07-13
CN111132700A (zh) 2020-05-08
IL272291B2 (en) 2025-06-01
BR112020001785A2 (pt) 2020-09-29
IL272291A (en) 2020-03-31
US20200197545A1 (en) 2020-06-25
IL272291B1 (en) 2025-02-01
EP4424378A2 (en) 2024-09-04
ES3011272T3 (en) 2025-04-07
KR20200064057A (ko) 2020-06-05
EP4424378A3 (en) 2024-12-11
US12453787B2 (en) 2025-10-28
KR20240027896A (ko) 2024-03-04
EP4000640A1 (en) 2022-05-25
FI3658194T3 (fi) 2025-02-28
KR102752620B1 (ko) 2025-01-10
HUE070098T2 (hu) 2025-05-28
WO2019020831A1 (en) 2019-01-31
US12390540B2 (en) 2025-08-19
MX2020000352A (es) 2020-08-17
IL318092A (en) 2025-02-01
EA202090370A1 (ru) 2020-05-25
AU2024200440B2 (en) 2025-04-24
JP2020528461A (ja) 2020-09-24
PT3658194T (pt) 2025-02-13
PL3658194T3 (pl) 2025-09-15
EP3658194B1 (en) 2024-11-27
US20250121102A1 (en) 2025-04-17
CN111132700B (zh) 2022-12-13
JP2022101601A (ja) 2022-07-06
AU2024200440A1 (en) 2024-02-08
JP7059372B2 (ja) 2022-04-25
DK3658194T3 (da) 2025-02-17
AU2018308699B2 (en) 2023-11-30
ZA202000467B (en) 2022-06-29
US20220370649A1 (en) 2022-11-24
AU2018308699A1 (en) 2020-01-23
SG11202000725WA (en) 2020-02-27
CA3071315A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2023007914A (es) Marcador radioactivo de modo dual y terapeuticos.
MX2023006274A (es) Agentes de imagenes de diagnostico del cancer.
PH12020550898A1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
MX2021013055A (es) Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos.
BR112016010927A2 (pt) Conjugado de fórmula
PH12018500285A1 (en) Bridge linkers for conjugation of a cell-binding molecule
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MA40074A (fr) Composés liant ras multivalents
NZ737471A (en) Hydrophilic linkers for conjugation
CO2017004471A2 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
MX2021008999A (es) Agentes radiotrazadores y agentes terapeuticos de modo doble, que se unen al antigeno de membrana especifico de la prostata.
EA201490644A1 (ru) Терапевтические пептиды
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
MX2023007810A (es) Compuestos de complejo de hierro para uso terapeutico.
MX374535B (es) Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico.
BR112017022252A2 (pt) conjugados de anticorpo-droga sítio-específicos
EP4678660A3 (en) Antibody against activin receptor type ii receptor for use in treating heart failure
MY209035A (en) Tricyclic compounds and their use
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates
WO2019125154A3 (en) Transition metal-based functional moieties for preparing cell targeting conjugates
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
MX2010001013A (es) Polisacaridos injertados por poliaminas para preparar composiciones radiofarmaceuticas.
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
WO2010116132A3 (en) Bisphosphonate compounds for chelating radionuclides